PMID- 9021816
OWN - NLM
STAT- MEDLINE
DCOM- 19970415
LR  - 20191024
IS  - 0888-0018 (Print)
IS  - 0888-0018 (Linking)
VI  - 14
IP  - 1
DP  - 1997 Jan-Feb
TI  - Engraftment failure following bone marrow transplantation in children with 
      thalassemia major using busulfan and cyclophosphamide conditioning.
PG  - 73-7
AB  - Thirteen children older than 3 years of age with beta-thalassemia major underwent 
      allogeneic bone marrow transplantation (BMT) from a full human leukocyte antigen 
      (HLA) matched sibling donor in a single institution. These patients received 
      busulfan (Bu). 16 mg/kg followed by cyclophosphamide (Cy) 200 mg/kg for 
      conditioning. Eight of the 13 patients (Group 1) engrafted and have a median age 
      of 13 years (range 5-15 years). The five patients (Group 2) who failed to engraft 
      have a median age of 6 years (range 3-8 years). The association with the 
      following factors was found to be statistically significant: age (older in Group 
      1), duration of nadir of white blood count (WBC) of < or = .1 x 10(9)/L (longer 
      in Group 1), and the dose of Bu administered to each patient calculated on the 
      basis of body surface area (higher dose in Group 1). The high rate of engraftment 
      failure (5 out of 13) may be related to the suboptimal systemic exposure of Bu in 
      younger children leading to inadequate bone marrow ablation when the standard 
      dose of 16 mg/kg is used.
FAU - Solh, H
AU  - Solh H
AD  - Department of Oncology, King Faisal Specialist Hospital and Research Centre, 
      Riyadh, Saudi Arabia.
FAU - Rao, K
AU  - Rao K
FAU - Martins da Cunha, A
AU  - Martins da Cunha A
FAU - Padmos, A
AU  - Padmos A
FAU - Giri, N
AU  - Giri N
FAU - Spence, D
AU  - Spence D
FAU - Clink, H
AU  - Clink H
FAU - Ernst, P
AU  - Ernst P
LA  - eng
PT  - Journal Article
PL  - England
TA  - Pediatr Hematol Oncol
JT  - Pediatric hematology and oncology
JID - 8700164
RN  - 0 (Immunosuppressive Agents)
RN  - 8N3DW7272P (Cyclophosphamide)
RN  - G1LN9045DK (Busulfan)
SB  - IM
MH  - *Bone Marrow Transplantation
MH  - Busulfan/*therapeutic use
MH  - Child
MH  - Child, Preschool
MH  - Cyclophosphamide/*therapeutic use
MH  - Female
MH  - *Graft Rejection
MH  - Humans
MH  - Immunosuppressive Agents/*therapeutic use
MH  - Male
MH  - Retrospective Studies
MH  - Statistics, Nonparametric
MH  - Transplantation Conditioning/*methods
MH  - beta-Thalassemia/*therapy
EDAT- 1997/01/01 00:00
MHDA- 1997/01/01 00:01
CRDT- 1997/01/01 00:00
PHST- 1997/01/01 00:00 [pubmed]
PHST- 1997/01/01 00:01 [medline]
PHST- 1997/01/01 00:00 [entrez]
AID - 10.3109/08880019709030887 [doi]
PST - ppublish
SO  - Pediatr Hematol Oncol. 1997 Jan-Feb;14(1):73-7. doi: 10.3109/08880019709030887.